MAROPITANT CITRATE ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C32H40N2O.C6H8O7
Molecular Weight	660.7963
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of MAROPITANT CITRATE ANHYDROUS

Structure Search

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.COC1=CC=C(C=C1CN[C@H]2C3CCN(CC3)[C@H]2C(C4=CC=CC=C4)C5=CC=CC=C5)C(C)(C)C

InChI

InChIKey=XDZPFSKCXRGRIO-PNXDLZEOSA-N

InChI=1S/C32H40N2O.C6H8O7/c1-32(2,3)27-15-16-28(35-4)26(21-27)22-33-30-25-17-19-34(20-18-25)31(30)29(23-11-7-5-8-12-23)24-13-9-6-10-14-24;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-16,21,25,29-31,33H,17-20,22H2,1-4H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t30-,31-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C32H40N2O
Molecular Weight	468.6728
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugs.com/pro/cerenia.html
Curator's Comment: Description was created based on several sources, including http://cerenia.com/ http://www.fda.gov/downloads/AnimalVeterinary/ucm062313.pdf

Maropitant (trade name Cerenia in the U.S. and other countries), used as maropitant citrate is a neurokinin (NK1) receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs, and was later approved for use in cats. Maropitant also has anti-nociceptive (analgesic) properties. Maropitant inhibits binding of substance P to NK-1 receptors. Substance P is an emetogen experimentally, and is found endogenously, along with NK-1 receptors, in the emetic center, chemoreceptor trigger zone, and in vagal afferent nerves in the gastrointestinal tract.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Substance-P receptor 8 Target ID: Q5DUB3 Gene ID: 403815.0 Gene Symbol: TACR1 Target Organism: Canis lupus familiaris (Dog) (Canis familiaris) Sources: https://www.drugs.com/pro/cerenia.html \| https://www.ncbi.nlm.nih.gov/pubmed/17610407	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Motion sickness in dogs 3 Sources: http://cerenia.com/	Preventing		Approved 8429	Cerenia Approved Use Cerenia is indicated for the prevention of acute vomiting and the prevention of vomiting due to motion sickness in dogs. Launch Date 2007

PubMed

Title	Date	PubMed
Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs.	2008 Dec	19000277
Acute vomiting in cats: rational treatment selection.	2010 Mar	20193913

Patents

Sample Use Guides

In Vivo Use Guide

For Prevention of Vomiting Due to Motion Sickness Administer Cerenia (Maropitant) Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days. Dogs should be fasted 1 hour prior to administration of Cerenia Tablets. Administer Cerenia Tablets 2 hours prior to travel.

Route of Administration: Oral

In Vitro Use Guide

Maropitant (0.1-10 uM) increased frequency of whole murine intestine contraction, decreased amplitude of contraction and totally inhibited motility index in a concentration-dependent manner.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:27:08 GMT 2023` Edited by `admin` on `Sat Dec 16 05:27:08 GMT 2023`
Record UNII	19364RWW06
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MAROPITANT CITRATE ANHYDROUS

Common Name

English

(2S,3S)-N-(5-(1,1-DIMETHYLETHYL)-2-METHOXYBENZYL)-2-(DIPHENYLMETHYL)-1-AZABICYCLO(2.2.2)OCTAN-3-AMINE 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID20235458